Johnson & Johnson’s Imaavy Faces Setback in Arthritis Trial
Johnson & Johnson has encountered a significant setback with its immunology product, Imaavy, which has failed to demonstrate efficacy in a Phase 2a clinical trial for treating rheumatoid arthritis. This…